STING1 and neoplasm: Additionally, a STING agonist (di-ABZI) and IDO inhibitor (1-methyl-d-tryptophan or 1-MT) combination inhibits tumor progression in the murine CRC via recruiting CD8+T cells and DCs and inhibiting immunosuppressive MDSCs (Table 1) [201].